Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00479024 · ClinicalTrials.gov registry record
Follow-up Study to Previous CARE Trial
A clinical trial of Moderate to Severe Chronic Kidney Disease, sponsored by Bracco Diagnostics.
- Completed
- Registry status
- 294
- Enrollment target
- 1
- Study location
NCT00479024 is a study of Moderate to Severe Chronic Kidney Disease that has completed, run by Bracco Diagnostics. The registered enrollment target is 294 participants. The trial reports 1 study location across 1 state.
The verdict
NCT00479024, a study of Moderate to Severe Chronic Kidney Disease, has completed, sponsored by Bracco Diagnostics.
- COMPLETED
- Registry status
- 294 participants
- Enrollment target
- 1
- Study location
Study Summary
To determine comparative 1-year outcomes in renally impaired patients who previously underwent cardiac angiography with Isovue®-370 or Visipaque™ 320 as part of the IOP-104 trial protocol and were evaluable for determination of post-contrast significant renal injury (defined as \>25% increase in SCr or \>25% increase in cystatin C).
Conditions Studied
Interventions
- DRUG iodinated contrast agent
Study Locations (1)
Alabama
- Cardiovascular Associates - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 294 participants |
| Start Date | 2007-06 |
| Est. Completion | 2008-04 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00479024
The ClinicalTrials.gov registry entry for NCT00479024 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 294 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bracco Diagnostics, which has 37 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Moderate to Severe Chronic Kidney Disease appearing as the primary indexed condition, and to 1 intervention - of which iodinated contrast agent is the first listed.
NCT00479024 reports 1 study location spanning 1 distinct geographic area - top geographies include Alabama.
Frequently Asked Questions
What is clinical trial NCT00479024 about?
NCT00479024 is a clinical study titled "Follow-up Study to Previous CARE Trial". To determine comparative 1-year outcomes in renally impaired patients who previously underwent cardiac angiography with Isovue®-370 or Visipaque™ 320 as part of the IOP-104 trial protocol and were evaluable for determination of post-contrast significant renal injury (defined as \>25% increase in SCr...
What is the current status of trial NCT00479024?
This trial is currently completed. The enrollment target is 294 participants. The study started on 2007-06. Estimated completion is 2008-04.
What conditions does trial NCT00479024 study?
This clinical trial studies the following conditions: Moderate to Severe Chronic Kidney Disease.
What interventions are being tested in trial NCT00479024?
The interventions under investigation include: iodinated contrast agent (DRUG).
Who is sponsoring clinical trial NCT00479024?
This trial is sponsored by Bracco Diagnostics, which has 37 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00479024 being conducted?
This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.